Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Sizheng Steven Zhao, Stephanie R. Harrison, Antoni Chan, Nick Clarke, Charlotte Davis, Joe Eddison, William J. Gregory, Gareth T. Jones, Helena Marzo-Ortega, Daniel J. Murphy, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Ben Thompson, Dale Webb, Max Yates, Karl Gaffney

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

Original languageEnglish
Article numberrkad039
JournalRheumatology Advances in Practice
Issue number2
Early online date15 May 2023
Publication statusPublished - 2023


  • AS
  • Axial spondyloarthritis
  • biologic
  • biosimilar
  • IL17
  • JAK inhibitor
  • switching
  • tapering
  • treat-to-target

Cite this